Qualigen Therapeutics Regains Nasdaq Compliance After Shareholder Approval Issue
Qualigen Therapeutics Inc. has regained compliance with Nasdaq Listing Rule 5635(b) after obtaining shareholder approval for a private placement transaction that changed control. The company is also compliant with Rule 5550(b)(1) for continued listing but will be monitored for one year. Non-compliance during this period requires a hearing request before the Nasdaq Hearing Panel.
Qualigen Therapeutics Inc. announced it received a letter from the Nasdaq Stock Market indicating non-compliance with Nasdaq Listing Rule 5635(b) due to a private placement transaction that resulted in a change of control without prior shareholder approval. The company has since obtained majority shareholder approval and regained compliance with the rule, closing the matter. Additionally, Qualigen received confirmation it is in compliance with Nasdaq Listing Rule 5550(b)(1) for continued listing, but will remain under a one-year Panel Monitor. If the company fails to remain in compliance during this period, it must request a hearing before the Nasdaq Hearing Panel. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qualigen Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-024647), on November 21, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
